These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022 [TBL] [Abstract][Full Text] [Related]
17. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G; Davies MA Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945 [TBL] [Abstract][Full Text] [Related]
18. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Flaherty KT Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578 [TBL] [Abstract][Full Text] [Related]